Undercarboxylated Osteocalcin Beta-Cell Proliferation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for metabolic syndrome, glucose intolerance, diabetes, atherosclerosis, and obesity do not effectively address the underlying energy metabolism disorders related to the OST-PTP signaling pathway, particularly the regulation of undercarboxylated osteocalcin levels.

Innovation Solution

The use of undercarboxylated/uncarboxylated osteocalcin or biologically active fragments thereof, along with agents that inhibit OST-PTP or gamma-carboxylase activity, to increase undercarboxylated osteocalcin levels, thereby enhancing insulin secretion, sensitivity, and glucose tolerance, and reducing weight gain and atherosclerotic plaque formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for metabolic syndrome and diabetes are used, then existing therapeutic protocols are maintained, but underlying energy metabolism disorders related to OST-PTP signaling pathway are not effectively addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidaddressing underlying energy metabolism disorders

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and isolates undercarboxylated osteocalcin as a specific therapeutic agent from the complex OST-PTP signaling pathway. By focusing on this single molecule that can be administered exogenously, the invention provides a targeted treatment that directly addresses the underlying energy metabolism disorders without requiring modification of the entire signaling pathway or multiple drug combinations.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Undercarboxylated osteocalcin serves as an intermediary substance that mediates between the OST-PTP signaling pathway and the metabolic effects. The compound acts as a bridge, translating the signaling pathway activity into tangible metabolic outcomes including improved insulin sensitivity, enhanced beta-cell function, and reduced atherosclerosis, thereby connecting upstream molecular events with downstream clinical benefits.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If undercarboxylated osteocalcin levels are increased through OST-PTP inhibition, then insulin secretion and sensitivity improve, but drug development complexity increases

Engineering Contradiction:

Improveinsulin secretion and sensitivityVSAvoiddrug development complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

Instead of inhibiting OST-PTP with complex small molecules or antibodies, the patent inverts the approach by directly administering undercarboxylated osteocalcin. This bypasses the need to develop inhibitors for the phosphatase enzyme and instead uses the downstream product itself as the therapeutic agent, simplifying the drug development pathway while achieving the desired metabolic effects.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The invention changes the parameter being targeted from enzyme activity (OST-PTP phosphatase activity) to hormone level (undercarboxylated osteocalcin concentration). By measuring and manipulating osteocalcin levels directly rather than enzyme activity, the therapeutic approach becomes more straightforward and clinically measurable, reducing development complexity.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If gamma-carboxylase activity is inhibited to increase undercarboxylated osteocalcin, then glucose tolerance improves, but carboxylation of other proteins may be affected

Engineering Contradiction:

Improveglucose toleranceVSAvoidcarboxylation of other proteins

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts undercarboxylated osteocalcin as a ready-made therapeutic product rather than attempting to inhibit gamma-carboxylase in vivo. By producing and administering the active form directly, the invention avoids the off-target effects of gamma-carboxylase inhibition on other carboxylatable proteins while still achieving the desired increase in bioactive osteocalcin levels.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses recombinant production to create copies of undercarboxylated osteocalcin for therapeutic administration. This allows precise control over the carboxylation state of the administered protein, ensuring it remains in the active undercarboxylated form without affecting the carboxylation status of other endogenous proteins through enzyme inhibition.

Inventive Principle:

Principle #26Copying

Data Source

PatentEP2073832B1Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass

Publication Date: 2013.09.04 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Figure 1A~1D
Figure 1E~1H
Figure 1I~1J

AI summary

The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.